|
INCREASED SERUM CONCENTRATION OF AMIODARONE
|
RITONAVIR SHOULD NOT BE CO-ADMINISTERED WITH CISAPRIDE,ASTEMIZOLE,MIDAZOLAM,TRIAZOLAM OR ERGOT DERIVATIVES BECAUSE COMPITITION FOR CYP3A4 BY EFAVIRENZ MAY RESULT IN INHIBITION OF OTHER DRUGS METABOLISM LEADING TO SERIOUS SIDE EFFECTS LIKE ARRHYTHMIAS
|
RITONAVIR SHOULD NOT BE CO-ADMINISTERED WITH CISAPRIDE,ASTEMIZOLE,MIDAZOLAM,TRIAZOLAM OR ERGOT DERIVATIVES BECAUSE COMPITITION FOR CYP3A4 BY EFAVIRENZ MAY RESULT IN INHIBITION OF OTHER DRUGS METABOLISM LEADING TO SERIOUS SIDE EFFECTS LIKE ARRHYTHMIAS
|
CONCURRENT USE WITH TERFENADINE, REPORTED TO SIGNIFICANTLY ALTER THE METABOLISM OF IT; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS, LIKE PROLONGED QT INTERVAL,CARDIAC ARREST,TORSADE DE POINTES,VENTRICULAR ARRHYTHMIAS, AND DEATH HAVE BEEN REPORTED
|
CO-ADMINISTRATION WITH HMG-COA REDUCTASE INHIBITORS THAT ARE METABOLIZED BY CYP3A PATHWAY, SUCH AS ATORVASTATIN, INCREASE THE RISK OF MYOPATHY & RHABDOMYOLYSIS
|
CO-ADMINISTRATION WITH HMG-COA REDUCTASE INHIBITORS THAT ARE METABOLIZED BY CYP3A PATHWAY, SUCH AS ATORVASTATIN, INCREASE THE RISK OF MYOPATHY & RHABDOMYOLYSIS
|
CO-ADMINISTRATION WITH HMG-COA REDUCTASE INHIBITORS THAT ARE METABOLIZED BY CYP3A PATHWAY, SUCH AS ATORVASTATIN, INCREASE THE RISK OF MYOPATHY & RHABDOMYOLYSIS
|
CO-ADMINISTRATION WITH HMG-COA REDUCTASE INHIBITORS THAT ARE METABOLIZED BY CYP3A PATHWAY, SUCH AS ATORVASTATIN, INCREASE THE RISK OF MYOPATHY & RHABDOMYOLYSIS
|
THEOPHYLLIN CLEARANCE IS INCREASED BY THE DRUG
|
THEOPHYLLIN CLEARANCE IS INCREASED BY THE DRUG
|
THEOPHYLLIN CLEARANCE IS INCREASED BY THE DRUG
|
THEOPHYLLIN CLEARANCE IS INCREASED BY THE DRUG
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM
|
CYTOCHROME P450 INHIBITORS MAY INHIBIT 25 HYDROXYLATION OF DOXERCALCIFEROL, HENCE FORMATION OF ACTIVE MOITY MAY BE HINDERED
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
INCREASED SEDATIVE EFFECT
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ANTIVIRALS LIKE RITONAVIR INCREASE PLASMA CONCENTRATION OF THE DRUG
|
ANTIVIRALS LIKE RITONAVIR INCREASE PLASMA CONCENTRATION OF THE DRUG
|
ANTIVIRALS LIKE RITONAVIR INCREASE PLASMA CONCENTRATION OF THE DRUG
|
ANTIVIRALS LIKE RITONAVIR INCREASE PLASMA CONCENTRATION OF THE DRUG
|
ANTIVIRALS LIKE RITONAVIR INCREASE PLASMA CONCENTRATION OF THE DRUG
|
ANTIVIRALS LIKE RITONAVIR INCREASE PLASMA CONCENTRATION OF THE DRUG
|
ANTIVIRALS LIKE RITONAVIR INCREASE PLASMA CONCENTRATION OF THE DRUG
|
ANTIVIRALS LIKE RITONAVIR INCREASE PLASMA CONCENTRATION OF THE DRUG
|
ANTIVIRALS LIKE RITONAVIR INCREASE PLASMA CONCENTRATION OF THE DRUG
|
ANTIVIRALS LIKE RITONAVIR INCREASE PLASMA CONCENTRATION OF THE DRUG
|
ANTIVIRALS LIKE RITONAVIR INCREASE PLASMA CONCENTRATION OF THE DRUG
|
ANTIVIRALS LIKE RITONAVIR INCREASE PLASMA CONCENTRATION OF THE DRUG
|
CO-ADMINISTRATION CAN INCREASE PLASMA LEVELS OF CICLESONIDE LEADING TO INCREASED CHANCES OF CUSHING SYNDROME
|
MAY POTENTIALLY INCREASE THE RISK FOR ACETAMINOPHEN INDUCED HEPATOTOXICITY
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
CO-ADMINISTRATION RESULTS IN DECREASED AUC OF ZIDOVUDINE; ROUTINE DOSE MODIFICATION IS NOT WARRANTED
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
RITONAVIR INCREASES PLASMA CONCENTRATION OF THE DRUG & SO INCREASED CHANCES OF SIDE EFFECTS
|
RITONAVIR INCREASES PLASMA CONCENTRATION OF THE DRUG & SO INCREASED CHANCES OF SIDE EFFECTS
|
RITONAVIR INCREASES PLASMA CONCENTRATION OF THE DRUG & SO INCREASED CHANCES OF SIDE EFFECTS
|
RITONAVIR INCREASES PLASMA CONCENTRATION OF THE DRUG & SO INCREASED CHANCES OF SIDE EFFECTS
|
RITONAVIR INCREASES PLASMA CONCENTRATION OF THE DRUG & SO INCREASED CHANCES OF SIDE EFFECTS
|
RITONAVIR INCREASES PLASMA CONCENTRATION OF THE DRUG & SO INCREASED CHANCES OF SIDE EFFECTS
|
RITONAVIR INCREASES PLASMA CONCENTRATION OF THE DRUG & SO INCREASED CHANCES OF SIDE EFFECTS
|
RITONAVIR INCREASES PLASMA CONCENTRATION OF THE DRUG & SO INCREASED CHANCES OF SIDE EFFECTS
|
RITONAVIR INCREASES PLASMA CONCENTRATION OF THE DRUG & SO INCREASED CHANCES OF SIDE EFFECTS
|